Bay­er fol­lows R&D deal spree by raid­ing Roche's can­cer group for its new re­search chief

The day af­ter Bay­er signed off on a $4 bil­lion deal de­signed to put the com­pa­ny among the lead­ers in gene ther­a­py de­vel­op­ment, the phar­ma gi­ant has re­cruit­ed a new chief for its R&D di­vi­sion. And they opt­ed for an ex­pert in the can­cer field.

Chris­t­ian Rom­mel, Roche’s head of dis­cov­ery and ear­ly-stage on­col­o­gy de­vel­op­ment, has been tapped to take over the job. Jo­erg Moeller, who got the top re­search post af­ter ear­ly- and late-stage de­vel­op­ment roles were com­bined 2 years ago, is hit­ting the ex­it “to pur­sue oth­er ca­reer op­por­tu­ni­ties.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER